NCT03114462View on ClinicalTrials.gov

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 9, 2017

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions
Malignant Neoplasms of Respiratory and Intrathoracic OrgansSquamous Cell Carcinoma of the Larynx
Interventions
RADIATION

Stereotactic Hypofractionated Radioablation

Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.

BEHAVIORAL

Questionnaires

Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Cancer Prevention Research Institute of Texas

OTHER

lead

M.D. Anderson Cancer Center

OTHER